Drug Survival in Patients with Psoriasis is Associated with the Availability of Biologic Medications

Psoriasis

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group.

doi: 10.1111/bjd.18981.

Psoriasis

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

J Eur Acad Dermatol Venereol.

Phan C, Beauchet A, Burztejn AC, Severino-Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj-Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour JP, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse AC, Kupfer-Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles-Tsimaratos N, Mery-Brossard L, Pallure V, Lons-Danic D, Bouilly-Auvray D, Beylot-Barry M, Puzenat E, Aubin F, Mahé E E, Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie

doi: 10.1111/jdv.15579.

Psoriasis

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

JAMA Dermatol.

Bronckers IMGJ, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Blume-Peytavi U, Szalai Z, Vleugels RA, Holland K, Murphy R, Puig L, Cordoro KM, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Seyger MMB, Psoriasis Investigator Group, the Pediatric Dermatology Research Alliance, and the European Working Group on Pediatric Psoriasis

doi: 10.1001/jamadermatol.2019.4835.

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

Psoriasis

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group

doi: 10.1111/bjd.17036.

Rheumatoid Arthritis

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register

Rheumatology (Oxford).

Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB

doi: 10.1093/rheumatology/kez671.

COMMENTED

Psoriasis

Drug survival of secukinumab for moderate-to-severe plaque psoriasis

Br J Dermatol.

Lee EB, Reynolds KA, Pithadia DJ, Wu JJ

doi: 10.1111/bjd.16572.

Psoriasis

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

J Am Acad Dermatol.

Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter MA

doi: 10.1016/j.jaad.2020.09.047.

Further Publications Rheumatology

Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: A nested case control study

Arthritis Rheumatol

Shalev Rosenthal Y, Schwartz N, Sagy I, Pavlovsky L

doi: 10.1002/art.41946

Related content

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register

Drug survival of secukinumab for moderate-to-severe plaque psoriasis

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: A nested case control study